# Medigene

Source: https://onco.cc/companies/medigene/  
OnCo record `medigene` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Medigene is a Munich-area biotech that develops T-cell receptor therapies and once sold a dendritic-cell vaccine programme; its earlier oncology products included the drug Veregen and phase 3 trials that carry its name.

## Summary

Medigene AG, founded in 1994 and based in Planegg near Munich, discovers T-cell receptors for engineered T-cell therapies against solid tumours and licenses them to partners. Earlier it developed and sold Veregen (sinecatechins) and EndoTAG-1, a cationic liposomal paclitaxel taken to phase 3 in pancreatic cancer by its licensee, and ran a dendritic-cell vaccine programme in acute myeloid leukaemia. Its trials are registered on ClinicalTrials.gov under Medigene as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: MediGene AG; Medigene AG
- Tags: ctgov-sponsor
- HQ: Planegg
- Type: cell-therapy
- Website: http://www.medigene.com

## Sources

- Official website: http://www.medigene.com
- ClinicalTrials.gov: trials led by MediGene AG: https://clinicaltrials.gov/search?lead=MediGene%20AG
- Wikidata: https://www.wikidata.org/wiki/Q1403929

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Dendritic cell vaccines](https://onco.cc/technologies/dendritic-cell-vaccines/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/medigene.json